Co-Authors
This is a "connection" page, showing publications co-authored by DAVID RANDALL GROSSHANS and MURALI CHINTAGUMPALA.
Connection Strength
2.696
-
Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group. Neuro Oncol. 2023 02 14; 25(2):224-233.
Score: 0.221
-
Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma. Cancer. 2021 Oct 15; 127(20):3865-3871.
Score: 0.198
-
Treatment age and neurocognitive outcomes following proton beam radiotherapy for pediatric low- and intermediate-grade gliomas. Pediatr Blood Cancer. 2021 08; 68(8):e29096.
Score: 0.196
-
Early radiotherapy preserves vision in sporadic optic pathway glioma. Cancer. 2021 07 01; 127(13):2358-2367.
Score: 0.194
-
Prospective, longitudinal comparison of neurocognitive change in pediatric brain tumor patients treated with proton radiotherapy versus surgery only. Neuro Oncol. 2019 06 10; 21(6):809-818.
Score: 0.171
-
Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. Neuro Oncol. 2019 05 06; 21(5):686-695.
Score: 0.170
-
Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
Score: 0.155
-
Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy. Clin Transl Radiat Oncol. 2016 Dec; 1:9-14.
Score: 0.142
-
Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 2014 Oct 01; 90(2):354-61.
Score: 0.122
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.062
-
Proton Therapy Mediates Dose Reductions to Brain Structures Associated With Cognition in Children With Medulloblastoma. Int J Radiat Oncol Biol Phys. 2024 May 01; 119(1):200-207.
Score: 0.058
-
Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023 Jul; 163(3):717-726.
Score: 0.057
-
Cognitive Sparing in Proton versus Photon Radiotherapy for Pediatric Brain Tumor Is Associated with White Matter Integrity: An Exploratory Study. Cancers (Basel). 2023 Mar 19; 15(6).
Score: 0.056
-
Superior verbal learning and memory in pediatric brain tumor survivors treated with proton versus photon radiotherapy. Neuropsychology. 2023 Feb; 37(2):204-217.
Score: 0.055
-
Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors. Neuro Oncol. 2022 09 01; 24(9):1571-1581.
Score: 0.054
-
Predicting neurocognitive function in pediatric brain tumor early survivorship: The neurological predictor scale and the incremental validity of tumor size. Pediatr Blood Cancer. 2022 09; 69(9):e29803.
Score: 0.053
-
A Prospective Evaluation of Fatigue in Pediatric Brain Tumor Patients Treated With Radiation Therapy. J Pediatr Hematol Oncol Nurs. 2022 Nov-Dec; 39(6):358-365.
Score: 0.053
-
Cognitive predictors of social adjustment in pediatric brain tumor survivors treated with photon versus proton radiation therapy. Pediatr Blood Cancer. 2022 06; 69(6):e29645.
Score: 0.052
-
Long-term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy. Pediatr Blood Cancer. 2021 09; 68(9):e29125.
Score: 0.049
-
Cognitive Risk in Survivors of Pediatric Brain Tumors. J Clin Oncol. 2021 06 01; 39(16):1718-1726.
Score: 0.049
-
Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A Surveillance, Epidemiology, and End Results analysis. Cancer. 2021 07 01; 127(13):2368-2375.
Score: 0.048
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.
Score: 0.048
-
Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis. Pediatr Blood Cancer. 2020 08; 67(8):e28373.
Score: 0.046
-
Reply to S.A. Milgrom et al. J Clin Oncol. 2020 07 01; 38(19):2212-2213.
Score: 0.046
-
Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020 02 10; 38(5):454-461.
Score: 0.044
-
Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. Pediatr Blood Cancer. 2020 02; 67(2):e28064.
Score: 0.044
-
Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27952.
Score: 0.043
-
Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatr Blood Cancer. 2019 09; 66(9):e27800.
Score: 0.043
-
Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiother Oncol. 2019 05; 134:143-150.
Score: 0.042
-
Attention, processing speed, and executive functioning in pediatric brain tumor survivors treated with proton beam radiation therapy. Radiother Oncol. 2017 07; 124(1):89-97.
Score: 0.037
-
Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. J Clin Oncol. 2016 Apr 01; 34(10):1043-9.
Score: 0.034
-
Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014 Dec 01; 90(5):1143-52.
Score: 0.031
-
Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011 Jun 02; 6:58.
Score: 0.025